Meghna Deshraj

In this episode of The Healthy Enterprise, host Brian Newsom discusses his journey in the biotechnology field, focusing on his role as CEO of Carrigent, a company specializing in cell and gene therapy. He elaborates on the innovative vector technology being developed for targeted payload delivery, the challenges of fundraising in the current market, and the integration of AI to enhance operational efficiency. Brian also shares insights into the importance of strategic partnerships and the ultimate goal of bringing therapeutic solutions to patients. In this conversation, the speaker discusses the importance of building long-term relationships in healthcare, particularly in the context of gene therapy. They share insights on leadership styles, emphasizing trust and autonomy within teams. The challenges of being a founder are explored, along with the need for inspiration and motivation in tough times. The discussion also touches on the intersection of science fiction and current scientific advancements, future trends in healthcare, and advice for aspiring professionals in the field.Chapters00:00 Introduction to Cell and Gene Therapy Innovations03:04 Exploring Vector Technology and Its Applications05:59 Brian Newsom's Journey: From Science to Business09:08 Leveraging AI and Technology in Biotech11:59 Navigating Fundraising Challenges in Biotech14:49 Strategic Partnerships and Market Positioning22:12 Building Long-Term Relationships in Healthcare23:27 Leadership Style and Team Dynamics26:00 The Challenges of Foundership28:32 Finding Inspiration and Motivation31:12 The Intersection of Science Fiction and Reality33:03 Future Trends in Healthcare35:34 Advice for Aspiring Professionals37:17 Navigating Tough Times in the IndustryGuest Information:Guest's Name: Brian NewsomGuest's Title/Position: Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/brian-newsom/Company / Affiliation:  Carrigent https://carrigent.com/Guest's Bio: Brian Newsom is the founding CEO of the vector technology company, Carrigent, as well as the VP of Business Development for the cell therapy CDMO, Theragent. Prior to this, Brian spent six years at KBI Biopharma and almost a decade at Thermo Fisher Scientific (and legacy companies) in business development. Brian’s technical background includes posts as Head of R&D at Opexa Therapeutics and five years at Baylor College of Medicine, Center for Cell and Gene Therapy. Brian began his career in cell therapy at Aastrom Biosciences, one of the industries pioneering companies, in 1992. Brian received his degree in Microbiology from Texas Tech University and an MBA from Texas A&M University.Takeaways:Brian Newsom is the CEO of Carrigent, focusing on cell and gene therapy.Carrigent is developing a next-generation payload delivery system.The company is exploring applications in oncology, metabolic, and neurodegenerative diseases.Brian transitioned from a scientific role to business development to have a broader impact.AI is being leveraged to create efficiencies in biotech operations.Fundraising in biotech is currently challenging due to market conditions.Strategic partnerships are essential for asset development and exposure.The ultimate goal is to partner with pharma and biotech for therapeutic development.Brian's diverse background provides a unique perspective in the industry.The end users of their technology will be pharma and biotech companies. Building long-term relationships is crucial in healthcare.Leadership involves trusting your team to do their jobs.Founders often struggle to let go of their vision.Inspiration can come from various sources, including literature.Science fiction often predicts future scientific advancements.Early diagnostics are essential for effective treatment.The healthcare industry is evolving with new therapies.Resilience is key in navigating industry challenges.Patient care should be the primary motivation for professionals.The future of healthcare will focus on curing chronic diseases.

In this episode of The Healthy Enterprise, Brent Lucas, CEO of Envoy Medical, shares his journey from lawyer to medical device executive and the evolution of Envoy’s pioneering hearing technologies. He discusses the challenges of leading innovation through clinical trials, navigating the shift from private to public, and the importance of community engagement. Brent also reflects on leadership lessons from sports, family entrepreneurship, and the power of patient stories in driving impact.Chapters:00:00 Introduction to Envoy Medical and Brent Lucas01:01 Brent's Journey in the Hearing Loss Industry05:03 Transforming Envoy Medical's Product Line09:04 The Impact of Cochlear Implants on Quality of Life13:01 Navigating Clinical Trials and Market Readiness15:10 Transitioning from Lawyer to CEO18:03 Leadership Challenges and Personal Management22:07 Family Influence and Entrepreneurial Spirit23:35 Going Public: A Strategic Decision24:24 Navigating the Public Market: Opportunities and Challenges27:39 Community Impact: Building Jobs and Relationships30:10 Leadership Lessons: From Sports to Business33:58 Overcoming Obstacles: Personal Growth and Imposter Syndrome36:19 Innovating with Technology: The Future of Medical Devices41:41 Marketing Strategy: Organic Growth Through Patient StoriesGuest Information:Guest's Name: Brent LucasGuest's Title/Position: Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/brent-lucas-envoy/Company / Affiliation: Envoy Medical https://www.envoymedical.com/Guest's Bio: Brent  Lucas is CEO and Board Member of Envoy Medical, an early-stage medical device company pioneering fully implanted hearing solutions, including the Esteem® active middle ear implant and the investigational Acclaim® cochlear implant. A principled medical device executive with a legal background, Brent brings 15+ years of leadership across enterprise functions—spanning strategy, finance, compliance, stakeholder engagement, and product development. Known for his transparent and motivating leadership style, he has guided Envoy through organizational turnaround, fundraising, and global commercialization efforts. With a track record of building inspired teams, streamlining operations, and driving patient-focused innovation, Brent is dedicated to improving quality of life through breakthrough medical technologies.Takeaways:Envoy Medical is a 30-year-old startup focused on hearing loss solutions.Brent Lucas became CEO during a pivotal transformation of the company.The company specializes in fully implanted hearing devices without external components.Cochlear implants can greatly enhance the quality of life for users.Navigating clinical trials is a lengthy but necessary process for product launch.Brent transitioned from a legal background to a leadership role in a medical device company.Effective communication is crucial for leadership success.Family influence played a significant role in Brent's entrepreneurial journey.The decision to go public was strategic for the company's growth.Brent emphasizes trusting instincts in decision-making as a CEO. Going public provides liquidity options for investors and employees.Community engagement is crucial for company culture and job creation.Leadership lessons can be learned from unexpected places, like sports.Imposter syndrome is a common challenge for leaders.Innovating with technology is essential in the medical device industry.Patient demand for fully implanted devices is expected to be high.Organic marketing through patient stories can be powerful.The transition to public markets comes with both opportunities and challenges.Maintaining focus on core products is vital for success.The surgical process for the new device is outpatient and efficient.

In this episode, Stefan Lukianov, founder and CEO of Salve Therapeutics, shares his journey in biotech and the creation of a healthcare app designed to improve patient experiences. He discusses leveraging technology to lower drug development costs—especially for rare diseases—and the role of real-time health data in patient empowerment. Stefan also reflects on challenges such as fundraising, the founder-to-CEO transition, and the importance of mentorship, collaboration, and clear vision in driving innovation within the healthcare industry.Chapters:00:00 Introduction to Salve Therapeutics and Patient Empowerment02:58 The Role of Technology in Drug Development06:00 Innovative Software Solutions for Rare Diseases08:58 Patient Self-Management and Mobile Health Apps12:06 Collaboration and Mentorship in Biotech14:56 Real-Time Health Data and Patient Engagement26:23 The Journey of App Development31:01 Navigating Fundraising and Investor Relations37:17 Transitioning from Founder to CEO44:30 The Importance of Thoughtfulness in LeadershipGuest Information:Guest's Name: Stefan LukianovGuest's Title/Position: Founder & CEOGuest's Linkedin: https://www.linkedin.com/in/stefan-n-lukianov-3a6862205/Company / Affiliation:  Salve Therapeutics https://www.salvetherapeutics.com/Guest's Bio: Stefan Lukianov is an artist, author, educator, businessman, and scientist with a background in computational bioengineering. He is the founder and CEO of Salve Therapeutics, where he is dedicated to advancing patient care through innovative viral and biologic therapies powered by advanced software solutions. His work centers on patient empowerment, with a focus on leveraging real-time health data and mobile health technologies to improve self-management, independence, and access to care. Beyond his role at Salve, Stefan is a strong advocate for mentorship and collaboration in the biotech industry, aiming to foster innovation, thoughtfulness, and a more patient-centered future for healthcare.Takeaways:Stefan Lukianov is the founder and CEO of Salve Therapeutics.Salve Therapeutics focuses on patient empowerment through technology.The company aims to reduce the cost of drug development for rare diseases.Their software is designed for drug developers to streamline the process.Real-time health data is crucial for patient engagement.Collaboration and mentorship are key in the biotech field.Mobile health apps can enhance patient self-management.The goal is to make healthcare more accessible and efficient.Patient independence is a priority in healthcare innovation.Technology is transforming the way healthcare is delivered.  The app has been in development since spring 2022.It's important to attract users with the app's design and functionality.Fundraising is a complex process that requires careful planning.Transitioning from founder to CEO involves balancing vision with operational realities.Thoughtfulness in decision-making leads to better outcomes.Listening to feedback is crucial for growth as a founder and CEO.Building relationships with potential customers is key to success.The healthcare app industry is heavily regulated, making development challenging.Networking and attending events can lead to valuable connections.Having a clear vision helps in managing investor expectations.

In this episode, Marc Koska shares his journey as a social entrepreneur and healthcare innovator. He discusses creating the K1 auto-disabled syringe, which has saved millions of lives by preventing the spread of blood-borne diseases, and his transition to Apiject to advance healthcare delivery with new injection technologies. Marc also reflects on lessons from biomimicry and product design, the challenges of global health in developing countries, and the importance of firsthand experience, social awareness, and data-driven decision-making in driving meaningful innovation.Chapters:00:00 Introduction to Marc Koska and His Innovations05:03 The Birth of the K1 Auto-Disabled Syringe12:09 Impact of the K1 Syringe on Global Health17:50 Transition to Apiject and New Innovations25:03 Future of Healthcare and Injection Devices26:59 Empowerment Through Creation29:20 The Birth of Biomimicry32:12 Social Impact and Empowerment35:24 Innovations in Design and Technology39:35 The Journey of Social Entrepreneurship45:55 Advice for Aspiring InnovatorsGuest Information:Guest's Name: Marc KoskaGuest's Title/Position: Co-founder and Head of Production DesignGuest's Linkedin: https://www.linkedin.com/in/marc-koska-5761181a/Company / Affiliation: ApiJect https://apiject.com/Guest's Bio: The inventor of the Apiject Platform and its first BFS injection device is Marc Koska, a highly honored “social entrepreneur.” The Prefilled Apiject Injector is designed for simplicity: Just prior to injection, a fill-finished Blow-Fill-Seal container and intramuscular needle hub are push-twisted together by a healthcare professional. Leading Apiject R&D, Marc and his team design drug delivery system prototypes that can reliably serve both advanced and developing markets. Through feedback from patients and healthcare providers, Marc has a deep understanding of customers and in building healthcare partnerships. This feedback is the foundation of Apiject’s Platform to ensure our single-use prefilled injector and future devices meet the needs of all. The Apiject Platform of drug delivery devices is designed to optimize manufacturing, warehousing, and transportation, using advanced technology, deliver cost efficiencies and accelerating time to market, and most importantly, save lives.Takeaways:Marc Koska invented the K1 auto-disabled syringe to prevent disease spread.The K1 syringe has saved approximately 12 million lives.Syringe reuse was a major transmission route for HIV.Marc's journey involved extensive research and learning about syringes.The K1 syringe design was a significant innovation in healthcare.Marc's work has had a profound impact on global health education.Apiject aims to provide safer and more accessible injection devices.The new injection devices are designed for self-administration.Environmental concerns are addressed with new syringe designs.Marc's career reflects a commitment to solving large-scale health problems. Empowerment comes from creating impactful solutions.Biomimicry is a study of nature's designs and interactions.Social entrepreneurship requires understanding the core truth of problems.Technology, like AI and 3D printing, enhances design processes.Traveling and seeing problems firsthand is crucial for entrepreneurs.Data and understanding all viewpoints are essential for success.Innovative design must consider social implications.Creating a supportive team culture is vital for success.Challenging the status quo is necessary for meaningful change.Success in social entrepreneurship requires a combination of passion and practicality.

In this episode of The Healthy Enterprise Podcast, Gautham Pasupuleti, CEO and Co-founder of Biodesign Innovation Labs, shares his journey in the medical device industry and the role of personal experiences in shaping innovation. He discusses challenges in healthcare entrepreneurship, the impact of mentorship and community, and his focus on AI and precision medicine, especially in cancer treatment, offering advice for aspiring entrepreneurs.Chapters:00:00 Introduction to Biodesign Innovation Labs02:47 Innovative Medical Devices for Critical Care05:50 AI and Precision Medicine in Cancer Care08:48 The Journey of Entrepreneurship in Healthcare12:05 Personal Experiences Shaping Innovation14:56 Building a Team and Community Engagement17:51 The Role of Mentorship and Collaboration21:07 Navigating the Healthcare Ecosystem23:56 Advice for Aspiring Innovators29:21 Journey into Medical Device Innovation32:53 Overcoming Personal Tragedy and Professional Challenges35:46 The Importance of Team Dynamics in Medical Innovation39:28 Leadership Lessons from Personal Loss44:37 Future Aspirations in Cancer Treatment and AI48:19 Advice for Aspiring EntrepreneursGuest Information:Guest's Name: Gautham PasupuletiGuest's Title/Position: Co Founder & CEOGuest's Linkedin:https://www.linkedin.com/in/gautham-pasupuleti-84884054/Company / Affiliation: Biodesign Innovation Labs https://biodesigninnovationlabs.com/Guest's Bio: Gautham Pasupuleti is the CEO and Managing Director of Biodesign Innovation Labs, a Bangalore- and Delaware-based medical device and healthcare company developing innovative and affordable critical care solutions. He leads a multidisciplinary team focused on life-saving technologies, including the patented RespirAID device, which supported hospitals across India during COVID-19. Gautham is a recognized innovator, having received awards such as Forbes India’s Ultimate 120 Pioneers of Change, the CISCO Global Problem Solver Pandemic Response Prize, and the Best Campus Startup Innovation Award from IIT Bombay. Previously, he was a researcher at MIT Media Lab and founded CornealX, an AI-based eye care startup now integrated into Biodesign Innovation Labs.Takeaways:Biodesign Innovation Labs focuses on life-saving medical devices.Respirate is an automated solution for manual ventilation.The company started its journey in 2017 with a focus on critical care.Personal experiences can drive innovation in healthcare.Community engagement is crucial for understanding healthcare needs.Mentorship plays a significant role in entrepreneurial success.AI solutions are being developed for early cancer detection.Building a team with diverse skills is essential for success.Hands-on experience is vital for understanding real-world problems.Workshops and seminars can provide valuable insights and connections. Gautham's journey began with a desire to innovate in medical technology.He collaborated on a VR and AR device for children's eye exams.After his brother's passing, he took on significant responsibilities in their startup.The importance of innovation in medical devices cannot be overstated.Team dynamics and diverse skill sets are crucial for success.Personal experiences can drive motivation to solve meaningful problems.Leadership requires making tough decisions and trusting your instincts.Gautham learned valuable lessons from his brother's mentorship.Resilience and persistence are key traits for entrepreneurs.Networking with experienced individuals can provide valuable insights. 

In this episode of the Healthy Enterprise podcast, Kevin Harris, President of CureMetrix, shares his journey in tech and the co-founding of CureMetrix, a company using AI to improve breast cancer detection through mammography. He discusses the role of breast arterial calcifications in health, the integration of AI in radiology, and the regulatory and cultural challenges of advancing AI in healthcare. Kevin also highlights leadership, mentorship, education, and strategies for growing a successful healthcare technology company, as well as the evolving opportunities AI brings to women’s health and healthcare professionals.Chapters:00:00 Introduction to AI in Healthcare03:49 The Genesis of CureMetrix09:10 Challenges in Mammography14:58 Innovations in Breast Cancer Detection21:10 Leadership and Team Dynamics at CureMetrix26:19 Building a Professional Culture27:37 Challenges in AI Adoption31:24 Navigating Regulatory Hurdles34:40 Sales Strategies in a Niche Market39:02 AI's Role in Women's Healthcare42:04 Opportunities in Healthcare CareersGuest Information:Guest's Name: Kevin HarrisGuest's Title/Position: President and co-founder Guest's Linkedin: https://www.linkedin.com/in/kevindavidharris/Company / Affiliation: CureMetrix https://curemetrix.com/Guest's Bio: Kevin Harris is the President and co-founder of CureMetrix. With over 25 years of leadership experience, Harris brings a demonstrated track record of success with particular expertise in new product ideation, implementation, market creation, and launch. As a strategic leader with deep operational expertise, Harris has led companies from inception through fundraising and mergers and acquisitions.  At CureMetrix, Harris is responsible for envisioning the AI-based products and services tied to breast cancer and breast arterial calcifications detection that are the foundation of the company’s business and are the first of their kind in the world.Takeaways:Kevin Harris has over 35 years of experience in technology.CureMetrix was founded to leverage AI in healthcare.The company focuses on improving mammography outcomes.Breast arterial calcifications can indicate serious health issues.AI can help reduce false positives in mammography.CureMetrix's software provides valuable insights to radiologists.Collaboration with data scientists is crucial for innovation.Building a strong team and mentorship is key to success.Understanding the healthcare landscape is essential for leaders.Patient outcomes can be significantly improved with AI. Building a company culture of professionalism reduces drama.AI is perceived as a tool rather than a replacement for doctors.AI operates consistently without human limitations.Regulatory challenges are significant in bringing AI to market.Sales strategies must target the right decision-makers in healthcare.Education is crucial for the adoption of AI in healthcare.AI can help radiologists focus on more critical cases.There are opportunities to automate certain healthcare tasks safely.AI can assist in pre-reading medical images to save time.The healthcare system needs to improve public education on health issues.

In this episode of The Healthy Enterprise, Anna Forsythe, founder and CEO of Oncoscope-AI, shares her journey from manually processing oncology data to creating an AI-powered platform that delivers real-time treatment insights, clinical guidelines, and research to support oncologists in an ever-evolving cancer landscape. She discusses the importance of reliable evidence in decision-making, the positive response from physicians using the free platform, and the role of systematic data reviews in building trust and efficiency. Beyond the technology, Anna reflects on her entrepreneurial path, the challenges and opportunities of leading in healthcare, and the importance of cultivating talent, mission-driven culture, and visionary leadership. The conversation concludes with her insights on business models, community impact, and the future of AI in advancing cancer care.Chapters:00:00 Introduction to Oncoscope-AI and Anna Forsythe03:04 The Need for Real-Time Oncology Data05:59 Transitioning from Manual to Automated Data Processing09:11 The Role of AI in Oncology12:13 Feedback and Response from Healthcare Professionals14:45 Data Sources and Systematic Reviews in Oncology18:02 Future Developments and Expanding Services21:53 AI in Research: Balancing Trust and Efficiency25:52 Business Model and Revenue Streams29:44 Personal Journey and Altruism in Business32:56 Challenges and Opportunities in Healthcare35:34 Leadership and Team Dynamics39:29 Visionary Leadership and Future AspirationsGuest Information:Guest's Name: Anna ForsytheGuest's Title/Position: Founder & CEOGuest's Linkedin: https://www.linkedin.com/in/anna-forsythe-3667143/ Company / Affiliation:  Oncoscope-AI https://oncoscope-ai.com/ Guest's Bio: Anna Forsythe, PharmD, MBA, is the Founder and CEO of Oncoscope-AI, the first platform to unify real-time oncology treatment data, clinical guidelines, research, and regulatory approvals—offered free to oncology professionals worldwide and often described as “Expedia for cancer care.” With a background spanning pharmacy, health economics, and executive leadership at Novartis, Bayer, and Eisai, Anna previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020), has taught health economics at Long Island University, and is a frequent industry speaker and author, with her 2022 JAMA Pediatrics article on conversion therapy ranked in the top 5% of all JAMA research outputs worldwide.Takeaways:Anna Forsythe is the founder and CEO of Oncoscope AI.Oncoscope AI provides real-time oncology treatment data and clinical guidelines.Doctors are overwhelmed with the volume of new evidence and guidelines.The platform aims to simplify access to oncology data, similar to Expedia for travel.AI is used to automate data processing but has limitations in consistency and accuracy.The platform is currently free for doctors to encourage adoption.Feedback from healthcare professionals is shaping the development of the platform.Data is sourced from publicly available databases like PubMed and clinical trials.The platform is expanding to include more cancer types and features.The response from users has been overwhelmingly positive, with over a thousand sign-ups. AI has a 0.2% error rate, necessitating careful review.A standardized database enhances research efficiency.The business model aims for profit while providing value.Personal experiences shape the desire to help others.Gathering data from doctors can lead to significant advertising revenue.The speaker is focused on launching multiple cancer treatments.Trust and transparency are crucial in AI innovation.Working with young talent is fulfilling and beneficial.Challenges in scaling the business are common in startups.Visionary leadership requires prioritization and focus.

In this episode, Sarah Bellenger, nurse veteran and entrepreneur, shares her journey creating Manage You, an app designed to fix inefficiencies in healthcare credentialing. She discusses the challenges of launching tech in a traditional industry, overcoming skepticism, and the importance of innovation and female leadership in healthcare. Sarah also reflects on funding disparities for women entrepreneurs and her vision for Manage You’s future impact on the industry.Chapters00:00 Introduction to Sarah Bellenger and Manage You03:07 The Need for Credentialing Solutions05:53 The Development Journey of Manage You08:48 Challenges in Healthcare Credentialing12:06 The App's Features and User Experience14:58 Expanding Manage You's Reach18:03 Future Developments and Scalability20:58 Entrepreneurial Insights and Challenges23:51 The Role of Women in Entrepreneurship26:47 Vision for the Future of Credentialing30:00 Conclusion and Call to ActionGuest Information:Guest's Name: Sarah BellengerGuest's Title/Position: Founder & Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/sarahrbellenger/Company / Affiliation: Manage You App https://www.manageyouapp.com/Guest's Bio: Sarah Bellenger is a clinician, Army veteran, and healthcare leader with over two decades of experience in patient care, team leadership, and system-wide operations. Her career spans cardiac ICU nursing, managing anesthesia teams across the U.S. and abroad, and even supporting executive health at the White House. After earning her MBA and serving in multiple leadership roles, Sarah recognized a recurring problem: capable professionals were burning out—not from the work itself, but from the inefficiencies surrounding it.Driven by her own experiences, including losing critical credentials during frequent relocations, Sarah founded Manage You—a mobile app that helps healthcare professionals and teams centralize documents, track deadlines, and simplify renewals. Her mission is clear: to reduce administrative burdens so clinicians can focus on what matters most—caring for patients.Takeaways:Sarah Bellenger is a nurse veteran and entrepreneur.Manage You addresses the inefficiencies in the credentialing process.Credentialing is a $39 billion industry with significant waste.The app allows users to store and manage their credentials efficiently.Users receive reminders for expiring documents directly on their phones.The app is designed to be user-friendly and secure.Sarah emphasizes the importance of networking and mentorship in entrepreneurship.Women face unique challenges in securing venture capital funding.The future of credentialing may involve digital verification and AI.Sarah is committed to making healthcare credentialing more efficient.

In this episode of The Healthy Enterprise, host Heath talks with Erin Morrow, Director of Product Management at Embark Veterinary, about how genetics and AI are transforming pet health. Erin shares her journey into product management, the role of dog DNA in better care decisions, and the challenges of building products in a fast-moving startup. She also dives into the integration of AI at work, the power of customer feedback, and creative marketing strategies—including collaborations with Disney. The conversation wraps with advice for aspiring professionals and a look at the future of technology in pet care.Chapters:00:00 Introduction to Embark Veterinary and Its Mission03:04 Erin Morrow's Journey and Background05:57 Understanding Dog DNA and Its Impact on Care09:03 The Role of Technology in Pet Care12:00 Future Innovations in Pet Health and AI14:59 Challenges in Product Development and Strategy17:55 The Value of Fractional Leadership20:49 Customer Feedback and Engagement Strategies26:49 Embracing AI in the Workplace30:12 Navigating Marketing Strategies38:41 Innovative Collaborations in Pet Care43:50 Advice for Aspiring ProfessionalsGuest Information:Guest's Name: Erin Morrow Guest's Title/Position: Director of Product ManagementGuest's Linkedin: https://www.linkedin.com/in/erin-morrow-68336829/Company / Affiliation: Embark Veterinary https://embarkvet.com/Guest's Bio: Erin Morrow is the Director of Product at Embark Veterinary, where she combines her passion for animals with cutting-edge technology to revolutionize pet care. With over 15 years of experience, she specializes in taking innovative products from initial concept through commercialization across SaaS, biotech, and educational technology sectors. Erin has a proven track record of building high-performing teams that consistently deliver products that users genuinely love. Her unique background includes a Bachelor's in Animal Science and Master's in Conservation Biology, giving her both the scientific rigor and deep empathy for animals and their caretakers that drives her customer-focused approach to product development.Takeaways:Embark Veterinary focuses on using genetics to enhance dog health.Erin Morrow has a diverse background in product management and animal science.Understanding a dog's DNA can significantly impact care decisions.The company has tested over 2 million dogs worldwide.AI and genomics are key to future pet health innovations.Customer feedback is crucial for product development.Fractional leadership can provide valuable insights and direction.Engaging with customers through social media enhances feedback.The importance of transitioning to a product-led organization.Continuous improvement in product offerings is essential for growth. We're starting to use AI internally and for customer-facing features.If you're writing an email, use ChatGPT for assistance.You still need to check your work; you are the subject matter expert.Finding the right tools is complex; experiment with different options.Word of mouth is still our strongest marketing engine.We collaborated with Colossus for our commercials.Our partnership with Disney was a significant campaign.We track brand awareness through customer feedback.Collaborations in the pet care space are yielding positive results.Follow your passion, but stay open-minded in your career. 

In this episode, Dr. Harsha Rajasimha discusses his journey as a biotech entrepreneur and the founder of Jeeva Clinical Trials. He shares insights into the inefficiencies of traditional clinical trials and how AI can streamline the process, making it more efficient and accessible. The conversation also touches on the importance of inclusivity in clinical research, the role of AI agents, and the personal motivations behind his work. Dr. Rajasimha emphasizes the need for a unified platform to enhance collaboration and reduce complexity in clinical trials, ultimately aiming to improve patient outcomes.Chapters:00:00 Introduction to Jiva Clinical Trials and Harsha Rajaseema02:50 The Clinical Trial Process: Challenges and Innovations05:51 AI in Clinical Trials: Enhancing Efficiency and Security08:59 The Role of AI Agents in Clinical Research11:55 Addressing Inequities in Clinical Trials15:02 Philanthropy and Patient Advocacy in Rare Diseases18:08 The Journey of an Entrepreneur: Insights and AdviceGuest Information:Guest's Name: Dr. Harsha K. RajasimhaGuest's Title/Position: Founder & Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/harsharajasimha/Company / Affiliation: Jeeva Clinical Trials https://jeevatrials.com/Guest's Bio: Dr. Harsha K. Rajasimha is a scientist, entrepreneur, and patient advocate, and the Founder & CEO of Jeeva Clinical Trials—an AI-driven platform making clinical research more efficient and accessible worldwide. He also serves as Founder and Chair of the Indo US Organization for Rare Diseases, building global collaboration to improve outcomes for patients with rare conditions. Motivated by personal loss, Harsha has dedicated his 20-year career in precision medicine and biotech to advancing rare disease research, patient advocacy, and the use of technology to accelerate clinical trials.Takeaways:Dr. Harsha Rajasimha is the founder of Jeeva Clinical Trials.Clinical trials typically take 8-10 years to complete.AI can significantly reduce the time and cost of clinical trials.The current clinical trial infrastructure is complex and fragmented.Jeeva aims to unify the clinical trial process with a single platform.AI agents will automate repetitive tasks in clinical trials.Inclusivity in clinical trials is crucial for diverse patient representation.Philanthropy plays a key role in Dr. Rajasimha's mission.The platform supports over 100 languages for global accessibility.Community support is essential for entrepreneurial success.

In this episode, Bill Wittmeyer discusses his journey as the CEO of Maggie's Breath, a company focused on using breath analysis for early detection of breast cancer. He shares insights into the technology behind breath analysis, the importance of early detection, and the challenges faced in the healthcare industry. Bill also reflects on the personal impact of breast cancer in his life and the future plans for Maggie's Breath, including clinical trials and funding efforts.Chapters:00:00 Introduction to Bill Wittmeyer and Maggie's Breath03:04 The Journey to Breath Analysis Technology05:55 The Importance of Early Detection in Breast Cancer08:56 Innovative Screening Methods and Their Implications11:49 The Role of Metabolic Compounds in Disease Detection15:05 Challenges in Implementing New Screening Technologies18:01 Mobile Screening Solutions for Breast Cancer20:59 Future Directions and Global Health Implications26:55 Clinical Trials and Market Opportunities30:02 Innovative Screening Technologies34:04 Navigating Regulatory Challenges36:10 The Journey of a Startup Founder41:45 Personal Loss and Legacy49:30 Fundraising and Community EngagementGuest Information:Guest's Name: Bill WittmeyerGuest's Title/Position: Founder & Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/bill-wittmeyer-b0628a/Company / Affiliation: Maggie's Breath https://www.maggiesbreath.com/ Guest's Bio: Bill Wittmeyer is the Founder and CEO of Maggie’s Breath (formerly Pulmostics Limited) where he applies advanced detection technologies—such as high-speed gas chromatography—to protect human health and the environment. Maggie’s Breath was renamed in honour of Bill’s late wife, Maggie, who lost her battle with breast cancer while working to advance life-saving diagnostics. Her vision lives on through the company’s mission: to create a revolutionary, non-invasive breath-based screening tool that can detect disease early and save lives. Bill’s leadership spans innovations in healthcare, environmental monitoring, and public safety, all driven by a commitment to turning personal loss into global impact for a healthier, more sustainable world.Takeaways:-Bill Wittmeyer is the CEO of Maggie's Breath, focused on breath analysis for breast cancer detection.-Maggie's Breath aims to provide a non-invasive screening tool for breast cancer.-The technology can analyze breath samples in just one minute.-Breast cancer is increasingly affecting younger women, necessitating early detection methods.-Current mammogram practices may not be effective for women with dense breast tissue.-Breath analysis could complement existing mammogram technologies.-The goal is to provide diagnostically actionable information at the point of care.-Maggie's Breath was named in honor of Bill's late wife, who passed away from breast cancer.-The company is seeking funding and partnerships to conduct clinical trials in Mexico.-Bill emphasizes the importance of early detection in improving survival rates and reducing treatment costs. 

In this episode, Dr. Steve Schutzer shares his journey from a Bronx kid to a prominent orthopedic surgeon and co-founder of Upswing Health. He discusses the importance of improving patient experiences in healthcare, the challenges faced in the industry, and the innovative solutions Upswing Health offers to streamline orthopedic care. The conversation highlights the significance of direct primary care, functional medicine, and the need for interoperability in healthcare systems. Dr. Schutzer emphasizes the entrepreneurial spirit required to address healthcare challenges and the importance of mentorship and effective communication in achieving success.Chapters:00:00 Introduction to Dr. Steve Schutzer and Upswing Health02:49 Dr. Schutzer's Journey in Medicine06:02 Mentorship and the Impact of Innovation in Orthopedics08:51 Creating Centers of Excellence in Joint Replacement11:55 Challenges in Healthcare and the Role of Legislation14:50 Direct Pay and Direct Primary Care Innovations18:01 Functional Medicine and Preventative Healthcare21:06 The Future of Healthcare and Entrepreneurial Medicine31:39 The Shift to Entrepreneurship32:25 Building Centers of Excellence34:48 Identifying the Ouch Moment36:12 Innovative Solutions in Orthopedics39:11 The Evolution of Orthopedic Management41:28 The Vision for Upswing44:20 Navigating Healthcare Challenges47:30 Interoperability in Healthcare51:27 The Future of Upswing55:45 The Role of Employers in Healthcare58:42 Marketing Strategies for UpswingGuest Information:Guest's Name: Steve Schutzer Guest's Title/Position: Co-Founder and Chief Medical Officer Guest's Linkedin: https://www.linkedin.com/in/steve-schutzer-md-81616125/Company / Affiliation: Upswing Health https://upswinghealth.com/Guest's Bio: Steve Schutzer is an orthopedic surgeon specializing in adult hip and knee reconstruction, with decades of experience leading joint replacement programs and advancing value-based orthopedic care. He believes in the power of connected communities and digital technologies—especially in today’s accelerating AI environment—working alongside compassionate human caregivers to solve complex medical challenges. Recognized as a focused, innovative, and visionary healthcare physician leader and strategist, Steve has an enduring obsession with improving the patient experience.Takeaways:Dr. Schutzer's journey reflects the unpredictability of career paths.The importance of mentorship in shaping a physician's career.Building centers of excellence can significantly improve patient care.Healthcare challenges are often rooted in financial disincentives.Direct primary care offers a promising alternative to traditional models.Functional medicine focuses on prevention and holistic care.Upswing Health aims to provide quick access to orthopedic care.Interoperability in healthcare is crucial for better patient outcomes.The rise of early onset cancers highlights the need for preventive care.Entrepreneurship in healthcare requires resilience and adaptability.

In this episode of The Healthy Enterprise, Jessicca Rege shares her groundbreaking work in cancer research at Sus Clinicals, where her team uses genetically modified “Oncopigs” to bridge the gap between preclinical and clinical trials. She discusses her path from academia to industry, her dual role as Chief Medical Officer at OncoScope AI, and her commitment to pushing the boundaries of oncology through innovative research, AI integration, and precision medicine. Jessicca also opens up about overcoming imposter syndrome, navigating the challenges of being a female leader, and mentoring the next generation of women in science. The conversation explores Sus Clinicals’ growth strategies in large animal research and offers inspiring insights for aspiring leaders on resilience, vision, and questioning the status quo.Chapters:00:00 Introduction to Jessicca Rege and Sus Clinicals07:30 The Oncopig Model: Revolutionizing Cancer Research18:04 The Journey of a Mutant Pig Farmer24:51 AI in Cancer Research and Future Directions27:14 Introduction to OncoScope AI and Leadership Roles28:36 Disruptive Leadership and Questioning the Status Quo30:45 Navigating Imposter Syndrome as a CEO32:42 The Challenges of Being a Female Leader35:41 Cultivating Future Female Leaders39:03 Steering Growth at Sus Clinicals41:33 Innovative Approaches in Large Animal Research45:34 Future Outlook and Goals for Sus Clinicals49:25 Advice for Aspiring LeadersGuest Information:Guest's Name: Jessicca RegeGuest's Title/Position: Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/jessiccarege/Company / Affiliation: Sus Clinicals https://susclinicals.com/Guest's Bio: Jessicca Rege is a pharmaceutical executive with extensive experience in oncology drug development, from pre-IND through commercialization. She has led R&D, regulatory, and medical affairs teams in both large pharma and biotech, guided in-licensing and acquisition strategies, and worked closely with global regulatory authorities. Jessica is also a trusted voice with investors, scientific leaders, and industry partners, advancing innovative cancer therapies worldwide.Takeaways:Jessicca Rege is passionate about transformative research in cancer.Sus Clinicals uses genetically modified pigs to advance cancer research.The Oncopig model allows for testing efficacy, safety, and metabolic effects.Cancer patients are often more knowledgeable about their conditions than expected.Jessica emphasizes the importance of empathy in patient care.The Oncopig model can replicate human cancers on demand.Precision medicine is becoming the standard in oncology.AI is being utilized in cancer research for systematic literature reviews.Jessica's journey reflects a commitment to improving patient outcomes.The integration of various medical professionals is crucial in cancer treatment. I am known as a disruptive leader.Imposter syndrome is always going to be with us.We want to continue to build models that enable researchers.We have a hundred percent success rate in being able to induce tumors.We believe the uptake is coming in.We could sell each of our different models to a different CRO.We hope to become a profitable company by 2027.You get more nos than you get yeses.I love the impact that I'm making on the teams.

In this episode, Braden Pan, CEO and founder of Resolve, discusses the significant issue of medical debt in America, which affects one in three individuals and is a leading cause of bankruptcy. He shares his personal journey that led him to create Resolve, a company dedicated to helping patients navigate and reduce their medical bills. Braden elaborates on the challenges of founding a startup, the integration of AI in their processes, and the importance of negotiating with hospitals. He also emphasizes the need for co-founders and the evolution of his leadership style as the company grows. The conversation highlights the future of Resolve, focusing on B2B expansion and the broader goal of addressing various types of debt.Chapters:00:00 Introduction to Resolve and Medical Debt03:11 Braden's Personal Journey and Founding Resolve06:11 Navigating the Complexities of Medical Billing09:05 The Role of AI in Medical Billing Solutions12:05 Understanding Hospital Billing Practices14:47 The Impact of Medical Debt on Patients17:58 Marketing Strategies and Patient Success Stories20:53 Future Directions for Resolve22:37 Navigating Financial Aid in Healthcare25:22 The Role of a Founder and CEO30:40 Shifting Business Strategies and Messaging32:14 Future Aspirations and Goals35:25 Leadership Evolution and Team Dynamics39:34 Advice for Aspiring Founders and Co-foundersGuest Information:Guest's Name: Braden PanGuest's Title/Position: CEO and FounderGuest's Linkedin: https://www.linkedin.com/in/bradenpan/Company / Affiliation: Resolve https://www.resolvemedicalbills.com/Guest's Bio: The idea for Resolve was sparked in 2016, when founder Braden Pan received an outrageous hospital bill for a brief, 15-minute consultation. Frustrated by the complex and opaque billing process, Braden set out to find a better way. That experience became the foundation for Resolve—a company dedicated to helping Americans fight back against unfair medical bills. Since then, Resolve has tackled all types of healthcare billing challenges, partnering with experts across the healthcare ecosystem to reduce financial stress and bring greater transparency to the system.Takeaways:Medical debt is a massive issue affecting many Americans.Resolve has saved patients over $55 million on medical bills.Braden's personal experience with medical debt inspired him to start Resolve.The healthcare system is complex and often designed to confuse patients.AI is being integrated into Resolve's processes to improve efficiency.Hospitals often prefer working with Resolve to lower their collection costs.Financial aid programs exist but are underutilized by patients.Braden emphasizes the importance of having a co-founder.Leadership evolves over time, especially in a startup environment.The future of Resolve includes expanding services to address all types of debt.

In this episode we will meet with Stephanie Dorwart, CEO of Altius Healthcare Consulting Group, for a wide-ranging conversation about how healthcare is changing—and what leaders need to do to keep up. We talk about the long-term impact of COVID-19, the growing role of data in driving smarter operations, and why strong, accountable leadership matters more than ever. Stephanie also shares her own journey from math teacher to healthcare CEO, and offers insights on the future of the industry—from the rise of telehealth to the unique challenges facing rural health systems.Chapters:00:00 Introduction to Altius Healthcare Consulting02:46 Stephanie's Journey into Healthcare06:50 Impact of COVID-19 on Healthcare Innovation10:32 The Role of Data in Healthcare12:02 Empowering Leaders through Data14:28 Building Trust and Accountability in Leadership18:13 The Importance of Continuous Improvement in Healthcare22:31 Navigating Leadership Development30:12 The Entrepreneurial Leap37:59 Innovations in Healthcare41:14 Vision for the Future of AltiusGuest Information:Guest's Name: Stephanie DorwartGuest's Title/Position: Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/stephanie-dorwart/ Company/Affiliation: Altius Healthcare Consulting Group https://altiushcg.com/Guest's Bio: Stephanie Dorwart is the CEO of ALTIUS, a healthcare consulting firm she rebranded and now leads with a hands-on, results-driven approach. With over 15 years of experience in performance improvement and labor management, she’s worked with hospitals of all sizes—from rural facilities to large academic medical centers—helping them improve financial performance, patient outcomes, and staff satisfaction. Known for her analytical expertise and deep industry insight, Stephanie consistently delivers measurable ROI and lasting client impact. Takeaways:Altius focuses on improving financial and operational performance in healthcare.Stephanie transitioned from teaching to healthcare due to a passion for data and patient care.COVID-19 accelerated the adoption of telehealth and innovative care models.Data in healthcare is relatively new and can significantly impact productivity.Empowering leaders with data helps them make informed decisions.Building trust within teams is essential for effective leadership.Accountability starts with setting clear goals and regular check-ins.Time management is crucial for leaders to think strategically.Rural healthcare systems face unique challenges and need support.The future of healthcare may focus more on preventive care and nutrition.

In this episode of The Healthy Enterprise as we dive into the world of sustainable innovation with Yuliana Mihaylova, a biotech executive and co-founder of OliveBio. Discover how Yuliana's journey from a PhD in genetics to an entrepreneur is paving the way for eco-friendly alternatives to petrochemical plastics. Learn about the challenges and triumphs of creating scalable bioplastics and the role of AI in revolutionizing production processes.Chapters:00:14 Introduction to OliveBio and Yuliana's Background02:01 The Motivation Behind OliveBio: Tackling Plastic Pollution06:15 Understanding PHAs: A Sustainable Bioplastic Solution11:59 OliveBio's Innovative Production Process for PHAs15:57 Applications and Future of Bioplastics18:21 Yuliana's Entrepreneurial Journey and Challenges22:36 Leveraging AI and Automation in Biotech33:13 Marketing and Growth Strategy for OliveBio36:49 Vision for OliveBio's Future Impact39:43 Key Learnings and Advice for Aspiring InnovatorsGuest Information:Guest's Name: Yuliana MihaylovaGuest's Title/Position: CEO & Co-FounderGuest's Linkedin: https://www.linkedin.com/in/yulianamihaylova/Company / Affiliation: OliveBio https://olivebio.com/Guest's Bio: Yuliana Mihaylova is a seasoned biotech executive and the team’s mission enforcer. After completing her Genetics PhD and post-doctoral research at the universities of Nottingham and Oxford, respectively, she worked in biotech and pharma management consulting, where she helped companies develop their asset commercialization and market access strategies. From 2019 to 2024, Yuliana was part of the executive team at Basepaws, a pet genetics company, acquired by the animal pharma startup Zoetis in 2022. As Basepaws’ Head of R&D, she led the development and refinement of new technologies and scientific products and was a key stakeholder in the translation of scientific discovery into business strategy.Yuliana believes strongly in the power of cross-disciplinary collaboration and innovative thinking to solve the world’s most pressing environmental challenges.Takeaways:OliveBio, co-founded by Yuliana Mihaylova, is developing scalable, affordable bioplastics to combat plastic pollutionFocuses on PHAs, biodegradable polymers from renewable sources that leave no microplasticsUses enzyme-based production instead of bacterial fermentation for better precision and lower costsPHAs have broad applications: packaging, single-use items, agriculture, 3D printing, and medical uses like suturesYuliana’s entrepreneurial journey includes adapting quickly, embracing failure, and bootstrapping with limited resourcesAI is integrated into OliveBio’s production systems and daily operations to enhance efficiency and accuracyMarketing strategy targets B2B2C—engaging businesses and influencing consumer demandLong-term vision is to build a sustainable, impactful company rather than seeking early acquisition

In this episode of the Healthy Enterprise podcast, David Georges, North American president of Koning Health, discusses his extensive experience in the breast imaging industry and the innovative BreastCT technology. He shares insights into the challenges of traditional mammography, the importance of early detection, and the potential of BreastCT to revolutionize breast cancer screening. The conversation also touches on the integration of AI, the global market expansion of the technology, and the significance of mentorship and leadership in driving change within healthcare.Chapters:00:00 Introduction to Breast Imaging Innovations02:49 David Georges' Journey in Breast Cancer Detection06:02 The Evolution of Breast Imaging Technology08:54 Challenges in Mammography and Patient Compliance11:58 Commercialization of BreastCT Technology14:46 Navigating Change in Medical Imaging18:11 Global Expansion and Future Vision for Koning Health20:45 The Impact of BreastCT on Patient Experience23:51 Addressing Resistance and Building Trust in New Technology26:58 The Future of Breast Imaging and Biopsy Procedures30:33 Understanding the Breast Imaging Industry32:28 The Role of AI in Breast Imaging34:04 Creating Commercial Viability for New Technology36:30 Educating Radiologists on New Imaging Techniques39:18 Building Confidence in Radiologists42:10 Transitioning to New Technologies in Imaging44:57 Career Guidance in Healthcare and Technology49:42 Mobile Breast Imaging Solutions54:08 The Economic Impact of Early Detection56:34 Future Prospects for Breast Imaging TechnologyGuest Information:Guest's Name: David GeorgesGuest's Title/Position: North American PresidentGuest's Linkedin: https://www.linkedin.com/in/david-georges-48a14020/Company / Affiliation: Koning Health https://www.koninghealth.com/Guest's Bio: David Georges has been a global business leader in Breast Imaging for the past twenty-five years, contributing to the introduction and substantial market growth of innovative products dedicated to the early detection of breast cancer including mammography, breast biopsy, computer aided detection, breast ultrasound and automated breast ultrasound. David has established manufacturing sites, supported luminary sites for new product introduction, and established physician and technologist training centers. He has held senior executive positions in companies such as Transworld, Lorad, Hologic, R2, SuperSonic Imagine, iVu and U-systems; the latter of which was purchased by GE.Since joining Koning, David has led the effort to move the company from a Research and Development group to one that is prepared for commercializing Koning’s KBCT. David’s industry relationships have introduced opportunities to establish critically important luminary partners. With a knowledge of global distribution, David has expanded the Koning installation base to Thailand, Qatar, and Netherlands.Takeaways:David Georges has 40 years of experience in breast imaging.BreastCT technology offers true isotropic 3D imaging without compression.Early detection of breast cancer significantly improves treatment outcomes.Patient compliance with mammograms is low due to discomfort.Koning Health aims to integrate BreastCT into existing facilities easily.The technology is gaining traction in global markets, including China and Australia.AI will play a crucial role in interpreting BreastCT images.Mobile BreastCT units are being deployed to increase accessibility.Healthcare economics favor early detection to reduce treatment costs.

In this episode, Eitan Akirav shares his journey from academia to the biotech industry, discussing the importance of mentorship, innovations in diabetes research, and the role of AI in healthcare. He emphasizes the need for a holistic approach to biomarkers and the future of oncology treatments. Eitan also provides insights into the challenges of consulting and the importance of building strong client relationships.Chapters:00:00 Introduction to Eitan Akirav and His Journey03:13 Transitioning from Academia to Industry06:03 The Role of Mentorship in Career Development09:04 Leadership in Academia vs. Industry11:58 Innovations in Diabetes Research and Patents15:02 The Future of Diabetes Detection and Prevention17:56 The Impact of AI in Healthcare21:03 Disruptive Innovations in Life Sciences25:31 The Concept of Cure in Cancer Treatment28:09 Balancing Technology and Human Touch in Healthcare29:52 The Economic Challenges of Drug Development32:50 Advice for Newcomers in the Science Industry36:46 Challenges in Consulting and Marketing Yourself44:44 Final Thoughts and Reflections on the JourneyGuest Information:Guest's Name: Eitan Akirav Guest's Title/Position: Founder & CEOGuest's Linkedin: https://www.linkedin.com/in/eitan-akirav/Company/Affiliation: KonKai Ventures https://www.linkedin.com/company/konkai-consulting/posts/?feedView=allGuest's Bio: Eitan Akirav is a seasoned biotech leader with over 17 years of experience bridging scientific innovation and business strategy. From leading global biomarker programs at Cerba Research to launching rapid COVID-19 diagnostics at Enzo, he’s driven impactful solutions across the biotech and healthcare landscape. Earlier in his career at NYU, he secured multimillion-dollar research funding and led clinical trials in autoimmunity. With work featured in PNAS and Nature Immunology, Eitan continues to advance science at the intersection of research, innovation, and real-world application.Takeaways:Eitan Akirav has over 17 years of experience in biotech.Mentorship plays a crucial role in career transitions.The transition from academia to industry can be challenging but rewarding.Innovations in diabetes research are focused on early detection.AI is a powerful tool that can save time in healthcare.The future of oncology may involve re-engineering immune cells.Customized medications based on genetic information are on the rise.The drug approval process is lengthy and complex.Newcomers in biotech should pursue their passion, not just titles.Consulting requires effective self-marketing and client relationship management.

In this episode of The Healthy Enterprise, Dr. Josh Funk, CEO of Rehab to Perform, shares his journey from college athlete to the head of a thriving, multi-location physical therapy practice. He dives into what it takes to build a business rooted in performance, culture, and innovation—especially in the evolving healthcare space. Dr. Funk discusses strategies for leadership, employee retention, and navigating growth while staying true to core values. From adapting during the COVID-19 pandemic to embracing AI and automation, Dr. Funk emphasizes the need for transparency, adaptability, and a relentless focus on patient empowerment to stay ahead in the industry.Chapters:00:00 Introduction to Dr. Josh Funk and Rehab 2 Perform01:07 Dr. Funk's Journey: From Athlete to Entrepreneur03:48 Growth of Rehab 2 Perform: From One to Eleven Locations06:38 Leadership and Culture: Infusing Vision Across Locations12:20 Retention Strategies: Keeping the Right Talent17:07 Challenges and Learning: Navigating Business Growth20:20 Adapting to COVID-19: Innovations and Changes24:01 Balancing Process and Human Connection27:10 Innovative Service Delivery in Physical Therapy30:03 The Role of Patient Participation in Recovery35:13 Growth Strategies for Rehab 2 Perform38:07 Navigating Marketing in a Competitive Landscape40:43 Challenges in the Healthcare System43:12 Leveraging AI for Efficiency48:40 Envisioning a Better Healthcare SystemGuest Information:Guest's Name: Dr. Josh FunkGuest's Title/Position: Founder & CEOGuest's Linkedin: https://www.linkedin.com/in/joshfunk/Company / Affiliation: Rehab 2 Perform https://rehab2perform.com/Guest's Bio: Dr. Josh Funk is the Founder and CEO of Rehab 2 Perform (R2P), a growing performance-based physical therapy company redefining how people experience rehab and recovery. With a model rooted at the intersection of movement, mindset, and long-term performance, Dr. Funk and his team focus on helping clients—from athletes and new moms to first responders and everyday movers—level up, not just heal.Under his leadership, R2P has grown into a multi-location, multi-state business that blends clinical excellence with a community-driven culture. The core philosophy? Treat people like athletes, build a better baseline, and help them perform for life.Dr. Funk also co-leads R2P Academy, an education and mentorship platform for clinicians, intrapreneurs, and future leaders in performance healthcare. A frequent speaker on topics like growth strategy, identity-based care, and scaling with soul, Dr. Funk is passionate about building businesses that make a lasting impact—inside and outside the clinic.Takeaways:Dr. Funk’s background as an athlete shapes his leadership style.Strong company culture is essential for multi-location success.Retention strategies are key when working with a young team.The pandemic accelerated innovation and adaptation.Balancing systems with human connection is critical in healthcare.Patient empowerment leads to better recovery and long-term results.Focusing on movement and performance—not just pain—is core to R2P’s approach.AI and automation can improve operations without replacing people.Transparent leadership builds alignment and trust.R2P plans to continue expanding its reach and impact.

In this conversation, Ed Fleischer shares his extensive career journey in the biotech industry, detailing his experiences from working in large pharmaceutical companies to transitioning into consultancy. He discusses the importance of staying current with industry trends, the impact of AI on biotech, and innovations in quality control. Edwin reflects on meaningful experiences that shaped his career, the significance of leadership and communication, and the motivation behind delivering life-changing medicines to patients.Chapters:0:00 - Introduction to Ed Fleischer2:09 - From Biotechnology to Consultancy10:00 - The Journey Through Major Pharma13:00 - Staying Current in a Dynamic Field14:43 - The Impact of AI on QC21:06 - The "Why" Behind the Work32:20 - Leadership and Authenticity36:51 - The Value of Public Speaking42:42 - Delivering on Trust46:11 - Conclusion and TakeawaysGuest Information:Guest's Name:  Ed FleischerGuest's Title/Position: Chief Executive Officer Guest's Linkedin: https://www.linkedin.com/in/ed-fleischer-a780482/Company/Affiliation: Beachside Compliance SolutionsGuest's Bio: Ed Fleischer is a seasoned Quality Control executive with a strong track record of leading quality improvement, operational excellence, and compliance initiatives in the biotechnology industry. With deep expertise in biotechnology processes, quality systems, and regulatory requirements across both domestic and international markets, he has successfully collaborated with agencies such as the FDA, EMA, and others. Ed is also the CEO of Beachside Compliance Solutions, a consultancy specializing in analytical and Quality Control challenges, where he offers independent, expert guidance to organizations navigating complex regulatory environments. He is passionate about developing talent and fostering a culture of quality at all levels of an organization.Takeaways:-He transitioned to consultancy after working in various pharmaceutical companies.-Staying current with regulations and industry trends is crucial for success.-AI is becoming increasingly important in the biotech field.-Innovations in quality control are revolutionizing the industry.-Ed's impactful experience with a patient highlighted the importance of their work.-Leadership requires authenticity and the ability to communicate effectively.-Diversity in teams leads to better problem-solving and innovation.-Consultants care about the outcomes of their work and follow up with clients.-The pharmaceutical industry is driven by the need to deliver safe and effective medicines.